SALATIO: Short Against Long Antibiotic Therapy for Infected Orthopedic Sites

Sponsor
Balgrist University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05499481
Collaborator
(none)
240
1
2
36.5
6.6

Study Details

Study Description

Brief Summary

The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:

  • SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

  • SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

Detailed Description

The optimal duration of postoperative, systemic antibiotic therapy for implant-related orthopedic infections, with or without implant removal, is unknown.

Retrospective studies suggest that a maximum duration of 6 weeks is not inferior to longer administrations; even if the infected implants are kept in place or during a one-stage exchange. Prospective-randomized trials (RCT) suggest that even shorter durations, such 3 or 4 weeks, are possible, when the implant is removed. Likewise, in prospective studies, 6 or 8 weeks of systemic antibiotics are not inferior to the current 12 weeks during DAIR (debridement, antibiotic and implant retention), or during the one-stage exchange; except for one single RCT suggesting a better outcome for 12 weeks in the substrata of arthroplasty infections undergoing the DAIR procedure.

However, these RCTs concern selected branches of orthopedic surgery; especially prosthetic joint infections. The investigators intend to expand these evaluations to all fields of orthopedic and hand surgery. The only exceptions would be spine surgery, for which a multicenter, separate RCT is already under way (SASI-trials). The second exception would be the treatment of implant-free diabetic foot infections, for which two RCTs are underway.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Short Against Long Antibiotic Therapy for Infected Orthopedic Sites
Anticipated Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Sep 15, 2024
Anticipated Study Completion Date :
Sep 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Long Antibiotic Arm

Without implant material in place: 6 weeks of systemic post-surgical antibiotic therapy With mateial in place 12 weeks of systemic post-surgical antibiotic therapy

Drug: Antibiotic
The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

Experimental: Short Antibiotic Arm

Without implant material in place: 3 weeks of systemic post-surgical antibiotic therapy With mateial in place 6 weeks of systemic post-surgical antibiotic therapy

Drug: Antibiotic
The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

Outcome Measures

Primary Outcome Measures

  1. Clinical remission related to the duration of total, postdebridement, antibiotic use [6 weeks postoperatively, or 1 year postoperatively in case of implant-related orthopedic surgery]

    Clinical assessment during routine surgical controls. Definition of clinical failure accoding to to sandard criteria in the literature (surgical revision, pain, local inflammation, discharge, several deep intraoperative bacterial tissue samples)

  2. Microbiological recurrence in relation to the total, postdebridement, antibiotic use [6 weeks postoperatively, or 1 year postoperatively in case of implant-related orthopedic surgery]

    Recurrence of infection, with the same pathogens, after completing the antibiotic treatment for the index infection

Secondary Outcome Measures

  1. Description of all clinical failures of any sort [6 weeks postoperatively, or 1 year postoperatively in case of implant-related orthopedic surgery]

    Need for hospitalisation or revision surgery for any non-infectious failures related to the operation wound (hematoma, seroma, internal (closed) fractures, dislocation of implants)

  2. Adverse events in each study arm, and in relation to the antibiotics used [6 weeks postoperatively, or 1 year postoperatively in case of implant-related orthopedic surgery]

    All adverse events during the therapy and follow-up time , with an emphasis on antibiotic-related adverse events (according to medical judgement). Numbers and descriptions.

  3. Length of hospital stay in acute care surgery (without rehabilitation) [6 weeks postoperatively, or 1 year postoperatively in case of implant-related orthopedic surgery]

    The duration of the hospital stay for every episode in both randomizing arm

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years on admission

  • Orthopedic bone and implant infections including musculoskeletal grafts

  • Intraoperative debridement with any surgical technique

  • 12 months of scheduled follow-up from hospitalization

  • Bacterial orthopedic infections of any nature

  • First or second episode of infection

Exclusion Criteria:
  • Mycobacterial, fungal, nocardial, and Actinomyces infections

  • Purely soft tissue infections

  • Non-resected cancer in the infection site

  • Purely intrasynovial infections (native joint septic arthritis)

  • More than three debridements performed for infection

  • Absence of at least one surgical intraoperative debridement

  • Spine infections (investigated in another trial)10

  • Diabetic foot infections (investigated in another trial)7

  • Documented endocarditis according to the Duke criteria

  • At least 2 prior infection episodes at the actual infection site

Contacts and Locations

Locations

Site City State Country Postal Code
1 Balgrist University Hospital Zurich Switzerland 8008

Sponsors and Collaborators

  • Balgrist University Hospital

Investigators

  • Principal Investigator: Ilker Uçkay, Professor, Balgrist University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Balgrist University Hospital
ClinicalTrials.gov Identifier:
NCT05499481
Other Study ID Numbers:
  • BASEC 2022-01012
First Posted:
Aug 12, 2022
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Balgrist University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022